This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Features of AMD treatment non-responders

Features of AMD treatment non-responders
Reviewed by Jonathan Chan

1 October 2019 | Jonathan Chan | EYE - Vitreo-Retinal

This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment epithelial detachment or >100um decrease of central retinal thickness (CRT) at three months comparing to baseline. Non-responders were defined as patients showing an increase in exudation or a decreased CRT of <100um; 19/365 eyes (5.2%) were non-responders. They were associated with choroidal vascular hyperpermeability on indocyanine green (ICG) angiogram and lower frequency of subretinal hypereflective materials on OCT imaging. In addition, this group of patients had a thicker central choroidal thickness (CCT) at baseline and after three monthly injections but not statistically significant. They also reported that additional intravitreal ranibizumab or PDT in combination with aflibercept were effective in 15/19 (79%) of the non-responder group. The authors concluded that aflibercept is effective in over 90% of the treatment naive AMD patients and identified that the non-responsiveness is associated with choroidal hyperpermeability in their series.

Characteristics of patients with neovascular age-related macular degeneration (AMD) who are non-responders to intravitreal aflibercept.
Hara C, Wakabayashi T, Toyama H, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2019;103:623-9.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency